How Do Macular Degeneration Agents Work?

Reviewed on 6/23/2021

What are macular degeneration agents and how do they work?

Macular degeneration agents are medications that slow down macular degeneration by preventing the growth of abnormal new blood vessels (neovascularization) in the retina. Each type of macular degeneration agent works uniquely to stop neovascularization.

Retina is the innermost layer of light sensitive tissue on the inside of the eyeball, which enables vision by sending signals through the optic nerve to the brain. Macula is the central part of the retina, which has a high concentration of photoreceptor cells and is responsible for central and color vision and fine details of images.

Age-related macular degeneration (AMD) occurs in people above 50 years of age and if untreated, can cause loss of central vision, although peripheral vision is unaffected. AMD is of two types:

  • Dry AMD: Dry AMD is the more common type, accounting for over 85% of the cases. In dry AMD, small white or yellow deposits known as drusen form on the macula which gets thinner. Progression of dry AMD is slow, but currently, there is no treatment for dry AMD.
  • Wet AMD: Although less common, wet AMD is more serious and progresses faster. Wet AMD is caused by abnormal neovascularization in the retina, which can leak blood or fluids into the retina, leading to scarring and degeneration of the macula. Wet AMD is treated with macular degeneration agents.

Most macular degeneration agents work by inhibiting the activity of a protein known as vascular endothelial growth factor (VEGF) that stimulates new blood vessel growth. Anti-VEGF macular degeneration agents are fragments of protein molecules that bind to VEGF and block their activity.

One of the macular degeneration agents is a photosensitizing drug that is used along with a laser beam to destroy neovascular growth.

How are macular degeneration agents used?

The anti-VEGF macular degeneration agents are all solutions administered as intravitreous injections. Vitreous is the clear gel-like substance that fills the eyeball space between the lens and the retina. The photosensitizing agent used in laser treatment of the macula is intravenously infused.

Macular degeneration agents are used to treat neovascularization of the retina, macula, fovea (a tiny pit in the center of macula) and choroid, the layer above the retina. Macular degeneration agents are used in the treatment of eye conditions including:

  • Age-related wet macular degeneration
  • Macular edema
  • Diabetic macular edema
  • Diabetic retinopathy
  • Myopic choroidal neovascularization
  • Macular degeneration with classic subfoveal choroidal neovascularization
  • Central serous chorioretinopathy


What causes dry eyes? See Answer

What are side effects of macular degeneration agents?

Most of the side effects of anti-VEGF macular degeneration agents are ocular, while the photosensitizing agent, which is administered intravenously, may cause more systemic side effects, in addition to the ocular side effects. Side effects of macular degeneration agents may include:

Anti-VEGF agents

Ocular side effects:

Systemic side effects:

Information contained herein is not intended to cover all possible side effects, precautions, warnings, drug interactions, allergic reactions, or adverse effects. Check with your doctor or pharmacist to make sure these drugs do not cause any harm when you take them along with other medicines. Never stop taking your medication and never change your dose or frequency without consulting your doctor.

What are names of some macular degeneration agents?

Generic and brand names of some macular degeneration agents include:

Anti-VEGF agents:

Photosensitizing agent:


Pink Eye (Conjunctivitis) Symptoms, Causes, Treatments See Slideshow

Health Solutions From Our Sponsors